There are a number of companies dealing in cancer research. But Seattle Genetics is quite different and more interesting. This is due to the passion displayed by its CEO Clay Siegall with regard to the innovations on which this company is focusing while making advancements in this cancer therapy. This is the reason why the stock price of his company has nearly tripled over past five years or so.
Clay Siegall is the CEO of Seattle Genetics. He has always had a passion for improving the lives of those who are suffering from cancer. This has been an area of interest for him since he started his career in the field of biomedical studies. Dr. Clay Siegall has been the chief executive officer of this company since 2002. He had co-founded it in 1998. He has tirelessly worked to lead this company to achieve great advancements in the field of cancer research. Hence they have come out with ground-breaking therapies for treating cancer patients.
Clay Siegall earned his Ph.D. in Genetics from the George Washington University. He has a long list of professional accomplishments. His career started as a Senior Research Investigator. This was at the Bristol-Myers Squibb Pharmaceutical Research Institute. Then he got promoted as Principal Scientist and later became a Staff Fellow as well as Biotechnology Fellow. This was at the National Cancer Institute. Then Clay Siegall launched Seattle Genetics.
He is deeply committed to implementing cutting-edge research developments. He has a true desire for helping patients as he wants to help to alleviate their suffering. It is this passion and drive that has helped Clay Siegall to take his company to great levels in terms of advancements in research.
It was under Dr. Clay Siegall’s leadership that Seattle Genetics was able to develop the first antibody-drug conjugates. ADCETRIS® was able to secure FDA approval in 2011. Now ADCETRIS® is focusing on expanding its global impact. Hence it is helping cancer patients in over 60 countries. It was the perseverance and dedication of Clay Siegall that aided the development as well as promotion of this ADC and made it available to so many patients around the world.